← All trials
NCT05648058
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 20, 2022
- Primary completion
- Oct 20, 2023
- Completion date
- Nov 20, 2023
- First posted
- Dec 13, 2022
- Last posted
- Dec 15, 2022
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of IraqLead sponsor
- Government of IraqStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.